Articles tagged with Parkinsons Disease
Researchers found that farnesol prevents loss of dopamine neurons and reverses behavioral deficits in mice, indicating its potential as a drug treatment for Parkinson's disease. The compound blocks the PARIS protein, which is involved in the progression of the disease.
Researchers have discovered distinct populations of neurons in the mesencephalic locomotor region that control different body movements. These findings could improve therapies for Parkinson's disease by targeting specific neuronal populations involved in postural changes and body extension.
A study published in Annals of Neurology found the SNCA gene has genome-wide significance in Latino PD patients, while a novel gene NRROS is identified as a potential risk factor. The research also shows a substantial overlap of PD genetic architecture between Europeans and Latinos.
A gene therapy trial has shown significant improvements in children with primary AADC deficiency, a devastating genetic disorder characterized by severe motor disability and developmental delay. The treatment targets neurons that produce dopamine, resulting in improved motor function, better mood, and longer sleep.
A non-toxic derivative of tetanus neurotoxin improves depression symptoms in rat models, lasting two weeks. Hc-TeTx inhibits serotonin transport by binding to neurotrophin receptors, suggesting potential for treating neurodegenerative diseases.
Researchers from UCPH discovered that a blockage in the pathway regulating nerve cell powerhouses, mitochondria, is the major cause of sporadic Parkinson's Disease. This dysregulation leads to accumulation of damaged mitochondria and neuronal death, resulting in dementia.
A new study shows participating in weekly dance training with music can improve daily living and motor function for those with mild-to-moderate Parkinson's disease. The research found significant improvements in experiences of daily living, including cognitive impairment, hallucinations, depression, and anxious mood.
A human endogenous peptide called LL-37 has been identified as a powerful blocker of toxic α-synuclein oligomers, which are responsible for neurodegeneration in Parkinson's disease. The discovery suggests that this naturally occurring molecule could be a safe and effective therapy to slow down the progression of the disease.
Researchers found no protection against Parkinson's and Lewy body dementias when reducing tau protein in brain neurons. Instead, the study highlights distinct roles of tau in these diseases compared to Alzheimer's, where reducing endogenous tau levels is protective.
Researchers discover that cytosolic dsDNA from mitochondria can cause cell death and neurodegeneration in PD patients. A new approach using DNAse II may help counteract this effect, potentially leading to a breakthrough in treating Parkinson's Disease.
A study by Van Andel Institute and Roche suggests that chronic gut inflammation may propel processes in the body leading to Parkinson's disease. The researchers found that gut inflammation triggers protein clumping in the colon and brain, which can clog molecular machinery and lead to Parkinson's symptoms.
A retrospective study of 33,360 patients found a 41% increased risk of Parkinson's disease in those with osteoarthritis. Patients with knee or hip osteoarthritis had a higher risk compared to others.
Researchers developed an AI system that analyzes 3D brain images to diagnose Parkinson's disease stages, providing a more precise diagnosis. The tool combines AI and 3D imaging to estimate severity based on neuronal damage.
Researchers found significant improvement in motor symptoms and reduction in medications 15 years after deep brain stimulation for Parkinson's disease patients. The study also showed a reduction in dyskinesia and 'off state' episodes, improving quality of life.
Scientists create synthetic melanin-like nanoparticles to overcome limitations of current dopamine delivery methods, achieving efficient and controlled release in the brain. The proposed method demonstrates promising results in reversing Parkinson's symptoms with high biocompatibility and non-toxicity.
University of Guelph researchers have discovered how entangled proteins in brain cells enable Parkinson's disease to spread. Misfolded alpha-synuclein aggregates spread to other parts of the brain, impairing areas responsible for motor function and cognition.
A research team identified the structure of hetero-oligomers causing Alzheimer's and Parkinson's diseases to overlap. The study reveals that these aggregates have more degrees of freedom, allowing peptides to be loosely packed on their surface.
Patients with REM sleep behavior disorder show signs of low blood flow and cognitive decline, suggesting a link between disrupted sleep and Parkinson's symptoms. The study aims to investigate the relationship between reduced blood flow and Parkinson's disease progression.
A rare mutation causes Parkinson's disease-like symptoms by disrupting dopamine transport, suggesting treatments targeting the transporters could alleviate symptoms. A malaria drug helps alleviate movement problems in genetically modified fruit flies with the mutation.
Researchers at the University of York developed a gel that adheres to nasal tissue, delivering levodopa directly to the brain. This innovation improves drug effectiveness and reduces dosage needs, potentially benefiting patients with Parkinson's disease.
A team of researchers used computational biology and leading-edge experiments to study alpha-synuclein, a protein linked to Parkinson's disease. They found stable conformations that can form complexes with other biomolecules, offering possibilities for developing drugs to regulate the protein's function.
Researchers identify 'antisense long non-coding RNA' regulating tau protein production, a crucial mechanism for brain cell function. The discovery may lead to new treatments for dementia-related diseases, including Parkinson's and Alzheimer's.
Understanding how tau protein is regulated in brain cells could lead to better treatments for Parkinson's and other neurological conditions. Researchers discovered that similar lncRNAs control the production of tau and other key proteins involved in brain function.
A nationwide cross-sectional study found that Parkinson's patients are more susceptible to severe COVID-19, with increased hospital mortality rates, especially in advanced age groups. The study highlights the need for optimal treatment of Parkinson's patients during the pandemic.
A study by Brigham and Women's Hospital has uncovered five genetic locations associated with progression in Parkinson's disease, identifying potential new targets for treatment. The research also developed a risk score to predict progression to dementia, a key factor in quality of life.
Researchers at UCSF Weill Institute for Neurosciences developed novel neurostimulation devices that monitor brain activity for months, pairing brain recordings with wearable monitors of movement. They identified patterns of brain activity corresponding to specific movement abnormalities associated with Parkinson's disease and demonstra...
A new study wirelessly records human brain activity during daily activities, allowing for adaptive deep brain stimulation and personalized treatment plans. This technology has significant implications for disease management and patient care.
Researchers discovered that a protein called VGLUT plays a key role in regulating sex differences in brain vulnerability to age-related dopamine neuron loss. Higher levels of VGLUT were found in female neurons, correlating with greater resilience to neurodegeneration and mobility deficiencies.
Researchers at HKUST create a novel optical tweezers-coupled Raman spectroscopy platform to analyze proteins in low concentrations, particularly IDPs. The study successfully characterizes the structural features of alpha-synuclein, an IDP linked to Parkinson's disease, at physiological concentration.
Researchers develop a robotic-medical device and procedure to safely induce presence hallucinations in Parkinson's patients, providing a new diagnostic tool for the disease. The study findings suggest that the test may help predict the severity of the disease's progression.
A survey by Parkinson's UK found that patients prioritize symptom improvement for balance, walking, and cognitive function. The study highlights the importance of person-centered management and care for improving quality of life.
Researchers found that Parkinson's disease patients demonstrate stable preferences for abstract art but diminished perception of movement in paintings. The study suggests that the brain's motor system interprets non-representational visual cues as abstract representations of movement, influencing aesthetic experiences.
A study by Florida State University College of Medicine researchers found a consistent association between neuroticism and an increased risk of developing Parkinson's disease. Adults with high neuroticism scores were 80% more likely to develop Parkinson's than those with lower scores.
Researchers are developing a new therapy to alleviate painful side effects of chronic drug treatment in Parkinson's patients. They're also working on a technology to safely locate abandoned oil and gas wells using drones, addressing an environmental hazard across the US.
A new study reveals that sleep disorders are a common symptom of multiple system atrophy, with greater severity correlating to more neuronal damage. The research found specific associations between sleep-related symptoms and MSA severity, including the parkinsonism subtype.
Researchers found a molecular link between Parkinson's disease and melanoma, with amyloid proteins α-synuclein and Pmel interacting in melanoma cells. This interaction may lead to reduced pigment production, contributing to the increased risk of melanoma in Parkinson's patients.
Researchers found that Parkinson's patients exhibit 53% lower step length synergy while crossing obstacles compared to healthy subjects. This impairment affects gait timing and foot positioning, making it difficult for patients to navigate obstacles safely, increasing the risk of falls.
Scientists have found that the parkin protein acts as a powerful antioxidant and storage site for dopamine radicals in brain cells. This discovery may lead to new treatments for early-onset Parkinson's disease by delivering antioxidants or a healthy copy of the parkin gene.
L-DOPA-induced dyskinesia is a major side effect of long-term medication, affecting millions worldwide. Researchers revealed the link between neuronal activity changes and dyskinesia, suggesting suppressing or restoring neurotransmission through key pathways may improve symptoms.
Researchers identified specific neural circuits in the basal ganglia linked to motor and non-motor Parkinson's symptoms. The findings provide a novel framework for understanding disease progression and may lead to more precise therapeutic strategies.
Research suggests that exercise can delay cognitive decline in people with Parkinson's disease who have the APOE e4 gene variant. This study found that greater physical activity at the start of the study reduced APOE e4-related cognitive decline two years later.
Researchers have made breakthroughs in deep brain stimulation, a therapeutic treatment for Parkinson's disease. Electrical stimulation at higher frequencies can successfully recalibrate dysfunctional circuits causing movement symptoms.
Researchers found that the Parkinon's gene PINK1 impairs the process of generating dopamine-producing neurons in the brain throughout adulthood. This discovery has significant implications for the future treatment of Parkinson's patients who develop the illness due to PINK1 defect or similar gene defects.
Researchers used AI software to analyze facial changes caused by Parkinson's disease, finding differences in apparent age and facial expressions. The study suggests AI could accelerate diagnosis and treatment for neurodegenerative diseases.
A team of bioinformaticians at Saarland University have identified microRNAs as potential biomarkers for Parkinson's disease using artificial intelligence methods. They found that the level of these non-coding RNAs in blood samples can track the course of the disease, particularly in the third decade of life and from around age 70.
Scientists have developed a technique to identify Parkinson's based on compounds found in sebum, a oily substance that coats the skin. The test shows promise for diagnosing the condition quickly and painlessly, with 85% accuracy.
Research from Queen Mary University of London has concluded that type 2 diabetes is associated with an increased risk of Parkinson's disease and may contribute to faster disease progression. Treating people with type 2 diabetes medications may reduce Parkinson's risk and slow its progression.
Parkinson's UK is investing £1.2 million in a project to refine a molecule that could be developed into a drug to protect dopamine-producing brain cells and slow down the progression of Parkinson's. The project aims to develop a treatment that can halt Parkinson's by boosting the function of brain cells' energy-producing mitochondria.
Researchers have discovered a link between immune cells in the blood and the development of Parkinson's disease. The study found that changes in these immune cells can lead to inflammation and neuronal activity loss in the brain, even before symptoms appear.
Researchers at Texas A&M University discovered that cytisine reduces dopamine neuron loss in females, providing potential evidence for treating Parkinson's disease. The protective effect of cytisinex occurred only in female animal models, and combining it with estrogen produced a stronger effect.
Researchers at Osaka City University discover sesaminol protects against neuronal damage and increases dopamine levels in Parkinson's disease models. The study suggests sesaminol may be the first-ever medicine for Parkinson's disease, potentially derived from industrial waste.
A preliminary study found that golf was better than tai chi in improving balance and mobility for people with Parkinson's disease. Golf participants were also more likely to continue with the activity, which may be attributed to its popularity among older adults.
Grafting neurons from monkeys' own cells into their brains relieved debilitating movement and depression symptoms associated with Parkinson's disease. The autologous transplants showed significant improvements within six months, with dopamine levels doubling and tripled within a year.
A genetic study of Lewy body dementia suggests that the disease is caused by a spectrum of problems seen in both Alzheimer's and Parkinson's diseases. Five genes have been identified as critical to the development of Lewy body dementia, with variations in these genes also linked to increased risk of Alzheimer's and Parkinson's diseases.
Researchers have discovered that alpha-synuclein, a protein present in everyone's brains, sticks to the inner face of nerve cell membranes and can kill healthy brain cells. The study sheds new light on the origins of Parkinson's Disease, a neurodegenerative disorder affecting millions worldwide.
A monitoring system based on smartwatches detects movement issues and tremors in Parkinson's patients, allowing for remote monitoring and adjusted medication plans. The platform showed promising results, with 94% match between clinician evaluations and patient data.
Scientists have identified neurons responsible for rapidly stopping behaviors and actions in patients with Parkinson's disease. These 'stop signal neurons' are critical in canceling planned movements, a skill that is lost in the condition. The discovery has the potential to improve deep brain stimulation treatment outcomes.
Researchers found changes in gut microbiome composition correlate with higher levels of toxic bile acids in people with Parkinson's. The findings suggest bile acids may be a viable biomarker for diagnosing Parkinson's early and tracking its progression.
A large observational study found that taking terazosin for enlarged prostate is associated with a reduced risk of developing Parkinson's disease. Men taking terazosin were 12-37% less likely to develop the disease compared to those taking tamsulosin, according to the study published in JAMA Neurology.
Researchers used an 'organs-on-a-chip' system to model the influence of gut bacteria on brain health and found that short-chain fatty acids can worsen Parkinson's disease. The study suggests a link between lipid metabolism and neurodegenerative diseases, highlighting the complex interactions between the gut and brain.